Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease
Adult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potenti...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2019-01-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177 |
id |
doaj-fbcbd12ab38945678e22b75a87206a1c |
---|---|
record_format |
Article |
spelling |
doaj-fbcbd12ab38945678e22b75a87206a1c2020-11-25T03:59:37ZengThe Royal SocietyOpen Biology2046-24412019-01-019110.1098/rsob.180177180177Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative diseaseYi-Ying WuFeng-Lan ChiuChan-Shien YehHung-Chih KuoAdult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potential mechanisms underlying sporadic disease. Patient-derived induced pluripotent stem cells (iPSCs) can be differentiated into disease-relevant neurons, providing an unparalleled platform for in vitro modelling and development of therapeutic strategies. Here, we review recent progress in generating Alzheimer's, Parkinson's and Huntington's disease models from patient-derived iPSCs. We also describe novel discoveries of pathological mechanisms and drug evaluations that have used these patient iPSC-derived neuronal models. Additionally, current human iPSC technology allows researchers to model diseases with 3D brain organoids, which are more representative of tissue architecture than traditional neuronal cultures. We discuss remaining challenges and emerging opportunities for the use of three-dimensional brain organoids in modelling brain development and neurodegeneration.https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177neurodegenerative diseasealzheimer's diseasebrain organoidhuntington's diseaseinduced pluripotent stem cellsparkinson's disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yi-Ying Wu Feng-Lan Chiu Chan-Shien Yeh Hung-Chih Kuo |
spellingShingle |
Yi-Ying Wu Feng-Lan Chiu Chan-Shien Yeh Hung-Chih Kuo Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease Open Biology neurodegenerative disease alzheimer's disease brain organoid huntington's disease induced pluripotent stem cells parkinson's disease |
author_facet |
Yi-Ying Wu Feng-Lan Chiu Chan-Shien Yeh Hung-Chih Kuo |
author_sort |
Yi-Ying Wu |
title |
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
title_short |
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
title_full |
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
title_fullStr |
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
title_full_unstemmed |
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
title_sort |
opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease |
publisher |
The Royal Society |
series |
Open Biology |
issn |
2046-2441 |
publishDate |
2019-01-01 |
description |
Adult-onset neurodegenerative diseases are among the most difficult human health conditions to model for drug development. Most genetic or toxin-induced cell and animal models cannot faithfully recapitulate pathology in disease-relevant cells, making it excessively challenging to explore the potential mechanisms underlying sporadic disease. Patient-derived induced pluripotent stem cells (iPSCs) can be differentiated into disease-relevant neurons, providing an unparalleled platform for in vitro modelling and development of therapeutic strategies. Here, we review recent progress in generating Alzheimer's, Parkinson's and Huntington's disease models from patient-derived iPSCs. We also describe novel discoveries of pathological mechanisms and drug evaluations that have used these patient iPSC-derived neuronal models. Additionally, current human iPSC technology allows researchers to model diseases with 3D brain organoids, which are more representative of tissue architecture than traditional neuronal cultures. We discuss remaining challenges and emerging opportunities for the use of three-dimensional brain organoids in modelling brain development and neurodegeneration. |
topic |
neurodegenerative disease alzheimer's disease brain organoid huntington's disease induced pluripotent stem cells parkinson's disease |
url |
https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.180177 |
work_keys_str_mv |
AT yiyingwu opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease AT fenglanchiu opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease AT chanshienyeh opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease AT hungchihkuo opportunitiesandchallengesfortheuseofinducedpluripotentstemcellsinmodellingneurodegenerativedisease |
_version_ |
1724453851870789632 |